Evaluation of the paclitaxel-ifosfamide-cisplatin (TIP) combination in relapsed and/or metastatic cervical cancer.

Christos Kosmas,N. Mylonakis,George D Tsakonas,Georgios Vorgias,Nikolaos Karvounis,Nicolas Tsavaris,Theodoros Daladimos,Nickolas Kalinoglou,Nikolaos Malamos,Theodore Akrivos,A. Karabelis

Evaluation of the paclitaxel-ifosfamide-cisplatin (TIP) combination in relapsed and/or metastatic cervical cancer.

2009

Christos Kosmas
N. Mylonakis
George D Tsakonas
Georgios Vorgias
Nikolaos Karvounis
Nicolas Tsavaris
Theodoros Daladimos
Nickolas Kalinoglou
Nikolaos Malamos
Theodore Akrivos
A. Karabelis

Background: Recurrent or metastatic cervical cancer represents an aggressive malignancy with a high rate of locoregional and distant failure. Therefore, we evaluated the three-drug combination of paclitaxel–ifosfamide–cisplatin (TIP).

Keywords:

Pathology
Cisplatin
Medicine
Ifosfamide
Cancer
Metastasis
Malignancy
Cervical cancer
Paclitaxel
Chemotherapy

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations